| |
Trinity Life Sciences can partner with you to assess, benchmark, plan and implement. LET’S GO.
|
|
Today's Big NewsMay 16, 2023 |
|
Learn how modern software development is driving the future of clinical research and technology, specifically how it is impacting the next generation of IRT. Learn more.
|
|
| By Nick Paul Taylor Viking Therapeutics’ non-alcoholic steatohepatitis has sailed past another clinical test, this time a phase 2b that linked VK2809 to mean relative changes in liver fat of up to 51.7% without causing widespread gastrointestinal side effects. |
|
|
|
By Annalee Armstrong The COVID pandemic was a make or break moment for many a biotech. For Mammoth Biosciences, it may have been both. For Janice Chen, chief technology officer and co-founder, the whole journey has been wild. |
By Gabrielle Masson Eli Lilly’s Prevail Therapeutics is jotting down up to $1.5 billion for Scribe Therapeutics in hopes of writing some new CRISPR-based genetic medicines for neurological and neuromuscular diseases into history. |
Sponsored by Bridge Bank Venture debt is a type of debt financing obtained by early and growth-stage companies and typically used as a complementary method to equity financing. |
|
Tuesday, May 23, 2023 | 12pm ET / 9am PT Join us for this insightful webinar to explore why analytical development is often underestimated, and should go hand-in-hand with process development when addressing clinical and commercial manufacturing requirements, advantages of using integrated analytical services within the areas of process development and technology transfer, and more. Register now.
|
|
By Nick Paul Taylor DiaMedica Therapeutics thinks it has the data to get out from under a stubborn FDA clinical hold. Ten months after its phase 2/3 stroke clinical trial suffered the setback, the biotech is on the cusp of submitting evidence designed to explain the unexpected low blood pressure events and allay concerns. |
Sponsored by Cytel Developing a new life-saving drug or medical device is fraught with challenges. But while challenges often vary from program to program, one in particular is guaranteed: uncertainty. In this article, Dr Kim, CMO at Cytel, discusses the nature and consequences of the uncertainty challenge, as well as the options available to help pharmaceutical and biotechnology companies navigate it. |
By Helen Floersh The world’s second-ever private astronaut mission to the International Space Station will ferry a first-of-its-kind experiment that will test whether scientists can create induced pluripotent stem cells in microgravity. |
By Max Bayer Flagship is taking the sheet off its latest biotech venture, unveiling Metaphore Biotechnologies and equipping it with $50 million to get off the ground. The biotech is looking to capitalize on natural molecular mimicry to design a class of new medicines. |
By Annalee Armstrong Boundless Bio, the precision oncology company working on treatments for oncogene-amplified cancers, is amping up its fundraising with a new $100 million series C round backed by Leaps by Bayer and RA Capital Management. |
By Max Bayer The Foundation for the National Institutes has tacked on eight new rare diseases to its Bespoke Gene Therapy Consortium, partnering with research institutions to advance novel therapies. The foundation's near-term goal is funding development of the trials through phase 1/2 studies. |
By Angus Liu Just as biopharma's M&A prospects seemed to be improving, the U.S. antitrust watchdog is reportedly preparing to put a damper on dealmaking. The Federal Trade Commission is aiming to block Amgen’s proposed $27.8 billion acquisition of Horizon Therapeutics, Bloomberg reports. |
By Paige Minemyer CVS Health is closing down its clinical trials arm just two years after its launch, a company spokesperson confirmed to Fierce Healthcare. |
By Andrea Park Embecta has teamed up with Tidepool to add an automated insulin delivery algorithm to its insulin patch pump to create a closed-loop diabetes management system for Type 2 users. |
By Annie Burky During Fortune’s recent Brainstorm Health event, experts and advocates working to address the dangerous inequality Black mothers face spoke about what institutions can do to address the growing threat. The event came soon after national Black Maternal Health Week and began with a statement from the president proclaiming that “healthcare should be a right and not a privilege.” |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we discuss the rise of digital therapeutics and remaining barriers to implementation. We also talk about what it takes to fix the PBM industry. |
|
|---|
|
|
| WhitepaperChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookDiscover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
| Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| WhitepaperThis paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
